Aspire Biopharma Holdings, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $6,202 | — | — | — | — |
| Gross profit | -$116 | — | — | — | — |
| Operating income | -$19.4M | -$1.2M | — | — | — |
| Operating expenses | $19.4M | $1.2M | $1.3M | $976,345 | $25,475 |
| Cost of revenue | $6,318 | — | — | — | — |
| Cash from operations | -$4.9M | -$265,186 | -$653,107 | -$1.4M | -$238,596 |
| Share repurchases | — | $13.8M | $284.9M | — | — |
| Total assets | $1.3M | $147,989 | $20.0M | $300.2M | $293,221 |
| Total liabilities | $7.7M | $1.7M | $403,328 | $11.1M | $293,696 |
Shares outstanding 1.3M · Free float 98.5%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.